Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Akkermansia Muciniphila and Berberine on Prediabetes Among Obese Subjects
NCT05720299Completed
- Start
- Mar 2025
- Primary completion
- Jun 2025
- Modality
- Small Molecules, Live Biotherapeutic Products
- Countries
- 1
01
Overview
Randomised, double-blind trial in prediabetes comparing Akkermansia muciniphila group(AKK), Berberine group and Placebo group (3 arms). Primary endpoint: Glycosylated Hemoglobin at 12 weeks. Started Mar 2025; status: completed.
02
Drugs
akkermansia muciniphilaberberine
03
Conditions
prediabetes
Beyond the preview
Go deeper on NCT05720299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05720299.